TIGIT-blockade synergizes with PD-1/PDL-1 blockade to enhance anti-tumor CD8+ T-cell immunity in pre-clinical models, and is even effective in mouse tumors models that are resistant of PD-1 blockade, thus providing hope for clinical efficacy in patients with anti-PD-1 resistant tumors. Here, CD8A is linked to neoplasm.